US Patent

US12042559 — Gastroretentive dosage forms for sustained drug delivery

Formulation · Assigned to Amneal Complex Products Research LLC · Expires 2038-06-18 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects gastroretentive dosage forms that provide prolonged gastric residence time and sustained release of drugs, including pyridostigmine bromide.

USPTO Abstract

The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Drugs covered by this patent

Patent Metadata

Patent number
US12042559
Jurisdiction
US
Classification
Formulation
Expires
2038-06-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Amneal Complex Products Research LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.